121 filings
Page 6 of 7
8-K
qvj2bfdx
9 Mar 16
Zafgen Reports Fourth Quarter and Full Year 2015 Financial Results
12:00am
8-K
ndeu7fzxddpc
8 Mar 16
Zafgen Adds Thomas O. Daniel, M.D. to its Board of Directors
12:00am
8-K
xzvpe
18 Feb 16
Zafgen’s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves
12:00am
8-K
jqjpf puv
20 Jan 16
Zafgen’s Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints
12:00am
8-K
eddjxgprmmo
3 Dec 15
Zafgen Announces Beloranib IND Placed on Complete Clinical Hold
12:00am
8-K
mqih87tuuxbdyzcrc9d8
2 Dec 15
Zafgen Provides Clinical Update on Beloranib
12:00am
8-K
fey3 4stmky01kluzjb
10 Nov 15
Zafgen Announces Third Quarter 2015 Financial Results
12:00am
8-K
zpfgb6dre30a
22 Oct 15
Zafgen Announces Beloranib Program Update
12:00am
8-K
izfda7cmb1 o13m7ix2
16 Oct 15
Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials
12:00am
8-K
rdnwm64qdd5zx
15 Oct 15
Other Events
12:00am
8-K
r6mbqi74g9 22d76d0
30 Sep 15
Zafgen Announces Transition of Board of Directors
12:00am
8-K
jw3xfhf foh07mz
11 Aug 15
Zafgen Reports Second Quarter 2015 Financial Results
12:00am
8-K
3iskv50x qk4j3d
1 Jul 15
Submission of Matters to a Vote of Security Holders
12:00am
8-K
o1t qno67
12 May 15
Zafgen Reports First Quarter 2015 Financial Results
12:00am
8-K
0jr2g12
19 Mar 15
Zafgen Reports Fourth Quarter and Full Year 2014 Financial Results
12:00am
8-K
0r271mfmvcff lskjsx
12 Jan 15
Other Events
12:00am
8-K
ixnthfusd bap0q
21 Nov 14
Entry into a Material Definitive Agreement
12:00am
8-K
ynsidfpmosvkku 63
12 Nov 14
Zafgen Reports Third Quarter 2014 Financial Results
12:00am
8-K
ddz4sx4j
18 Sep 14
Departure of Directors or Certain Officers
12:00am
8-K
8ymh6 66tp6njjc1
13 Aug 14
Zafgen Reports Second Quarter 2014 Financial Results
12:00am